HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
Metrics: PDF 2015 views | HTML 1200 views | ?
Naoki Takegawa1, Kimio Yonesaka1, Kazuko Sakai2, Hiroto Ueda1, Satomi Watanabe1, Yoshikane Nonagase1, Tatsuya Okuno1, Masayuki Takeda1, Osamu Maenishi3, Junji Tsurutani1, Taroh Satoh4, Isamu Okamoto5, Kazuto Nishio2, Takao Tamura1, and Kazuhiko Nakagawa1
1Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
2Department of Genome Biology, Kinki University School of Medicine, Osaka, Japan
3Department of Pathology, Kinki University School of Medicine, Osaka, Japan
4Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan
5Center for Clinical and Translational Research, Kyushu University, Kyushu, Japan
Kimio Yonesaka, e-mail: email@example.com
Keywords: colorectal cancer, cetuximab, acquired resistance, human epidermal growth factor receptor 2, ctDNA
Received: August 21, 2015 Accepted: November 21, 2015 Published: December 02, 2015
Background: Patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS benefit from epidermal growth factor receptor (EGFR)-targeted therapy. However, patients who are treated with anti-EGFR antibodies will eventually develop the resistance to those agents. HER2 amplification is one of the mechanisms conferring resistance to anti-EGFR antibody therapy and could therefore be a potential therapeutic target. The aim of this study was to detect HER2 amplification in circulating tumor DNA (ctDNA) from patients with CRC and acquired resistance to anti-EGFR antibody therapy.
Results: Our data showed that 22% (4/18) of patients in the cohort exhibited HER2 amplification. One of these patients was found to be positive for HER2 amplification in matched tumor specimens collected after cetuximab therapy, at which point the patient had acquired cetuximab resistance, despite being negative for HER2 amplification prior to therapy.
Methods: We analyzed plasma ctDNA using digital polymerase chain reaction (PCR) from 18 patients with CRC, who had been treated with anti-EGFR antibody-based therapy (cetuximab) and subsequently acquired resistant cetuximab. HER2 gene copy number was analyzed using fluorescence in situ hybridization in tumor samples before and after acquisition of resistance to cetuximab-based therapy.
Conclusion: Analysis of plasma ctDNA by digital PCR could be useful for detecting HER2 amplification in patients with CRC who were resistant to anti-EGFR antibody therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.